Randall Moreadith - 22 Jan 2026 Form 4 Insider Report for Serina Therapeutics, Inc. (SER)

Signature
/s/ Randall Moreadith
Issuer symbol
SER
Transactions as of
22 Jan 2026
Net transactions value
-$7,225
Form type
4
Filing time
23 Jan 2026, 12:35:09 UTC
Previous filing
21 Jan 2026
Next filing
29 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Moreadith Randall Chief Scientific Officer 601 GENOME WAY, SUITE 2001, HUNTSVILLE /s/ Randall Moreadith 23 Jan 2026 0001301120

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SER Common Stock Options Exercise $150 +2,500 $0.0600 2,500 22 Jan 2026 Direct
transaction SER Common Stock Sale $7,375 -2,500 -100% $2.95 0 22 Jan 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SER Stock Option (right to buy) Options Exercise $0 -2,500 -0.76% $0.000000 326,186 22 Jan 2026 Common Stock 2,500 $0.0600 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The stock options are fully vested.